Therapeutic options for infections due to vancomycin-resistant enterococci

Bibliography

• Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-8
   PubMed Web of Science ®Google Scholar
• Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-21
   PubMed Web of Science ®Google Scholar
• Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000;13:686-707
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001;1:314-25
   PubMedGoogle Scholar
• National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992–April 2000. Am J Infect Control 2000;28:429-48
   PubMed Web of Science ®Google Scholar
• Information for the public about VRE. National Center for Preparedness, Detection, and Control of Infectious Diseases, 2008. Available from: www.cdc.gov/ncidod/dhqp/ar_VRE_publicFAQ.html [Accessed 25 February 2009]
   Google Scholar
• Schouten M, Hoogkamp-Korstanje J, Meis J, Voss A. Prevalence of vancomcyin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis 2000;19:816-22
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163-70
   PubMed Web of Science ®Google Scholar
• Moreno F, Grota P, Crisp C, et al. Clinical and molecular epidemiology of vancomycin-resistant Enterococcus faecium during its emergence in a city in southern Texas. Clin Infect Dis 1995;21:1234-7
   PubMedGoogle Scholar
• Dahms RA, Johnson EM, Statz CL, et al. Third generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant Enterococcus infection. Arch Surg 1998;133:1343-6
   PubMedGoogle Scholar
• Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-9
   PubMed Web of Science ®Google Scholar
• Tornieporth NG, Roberts RB, John J, et al. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-72
   PubMed Web of Science ®Google Scholar
• Ostrowsky BE, Venkataraman L, D'Agata EM, et al. Vancomycin-resistant enterococci in intensive care units. Arch Intern Med 1999;159:1467-72
   PubMedGoogle Scholar
• Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135:175-83
   PubMed Web of Science ®Google Scholar
• Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-33
   PubMed Web of Science ®Google Scholar
• Montecalvo MA, de Lencastre H, Carraher M, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16:680-5
   PubMed Web of Science ®Google Scholar
• Beezhold DW, Slaughter S, Hayden MK, et al. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis 1997;24:704-6
   PubMedGoogle Scholar
• Yamaguchi E, Valena F, Smith SM, et al. Colonization pattern of vancomycin-resistant Enterococcus faecium. Am J Infect Control 1994;22:202-6
   PubMedGoogle Scholar
• Klare I, Konstabel C, Mueller-Bertling S, et al. Spread of ampicillin/ vancomycin-resistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals. Eur J Clin Microbiol Infect Dis 2005;24:815-25
   PubMed Web of Science ®Google Scholar
• Willems RJ, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005;11:821-8
   PubMed Web of Science ®Google Scholar
• Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70
   PubMed Web of Science ®Google Scholar
• Diazgranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327-33
   PubMed Web of Science ®Google Scholar
• Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003;24:690-8
   PubMed Web of Science ®Google Scholar
• Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 2007;7:29
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26:43-9
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002–2005). Diagn Microbiol Infect Dis 2007;57:459-65
   PubMed Web of Science ®Google Scholar
• Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002–2004). Clin Microbiol Infect 2006;12:844-52
   PubMed Web of Science ®Google Scholar
• Ballow CH, Jones RN, Biedenbach DJ; North American ZAPS Research Group. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002;43:75-83
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Laing NM, Nichol KA, et al. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J Antimicrob Chemother 2003;52:382-8
   PubMed Web of Science ®Google Scholar
• Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996;156:2579-84
   PubMedGoogle Scholar
• Malathum K, Murray BE. Vancomycin-resistant enterococci: recent advances in genetics, epidemiology and therapeutic options. Drug Resist Update 1999;2:224-43
   PubMedGoogle Scholar
• Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995;1:249-53
   PubMedGoogle Scholar
• Hayden MK, Trenholme GM, Schultz JE, Sahm DF. In vivo development of teicoplanin resistance in VanB Enterococcus faecium isolate. J Infect Dis 1993;167:1224-7
   PubMed Web of Science ®Google Scholar
• Kawalec M, Gniadkowski M, Kedzierska J, et al. Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype. J Clin Microbiol 2001;39:4274-82
   PubMedGoogle Scholar
• Norris AH, Reilly JP, Edelstein PH, et al. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:1137-44
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27:1259-65
   PubMed Web of Science ®Google Scholar
• Ricaurte JC, Boucher HW, Turett GS, et al. Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. Clin Microbiol Infect 2001;7:17-21
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Gould CV, La Rosa LA, et al. Emergence of resistance to chloramphenicol among vancomycin-resistant enterococcal (VRE) bloodstream isolates. Int J Antimicrob Agent 2004;23:200-3
   PubMedGoogle Scholar
• Gould CV, Fishman NO, Nachamkin I, Lautenbach E. Chloramphenicol resistance in vancomycin-resistant enterococcal bacteremia: impact of prior fluoroquinolone use? Infect Control Hosp Epidemiol 2004;25:138-45
   PubMedGoogle Scholar
• Perri MB, Hershberger E, Ionescu M, et al. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002;42:269-71
   PubMed Web of Science ®Google Scholar
• Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999;43:211-7
   PubMed Web of Science ®Google Scholar
• Shrestha NK, Chua JD, Tuohy MJ, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003;35:12-4
   PubMed Web of Science ®Google Scholar
• Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med 2002;113(Suppl 1A):35S-44S
   Google Scholar
• Mutnick AH, Biedenbach DJ, Jones RN. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2003;46:63-8
   PubMed Web of Science ®Google Scholar
• Howe RA, Robson M, Oakhill A, et al. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant Enterococcus. J Antimicrob Chemother 1997;40:144-5
   PubMedGoogle Scholar
• Montecalvo MA, Horowitz H, Wormser GP, et al. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1995;39:794
   PubMed Web of Science ®Google Scholar
• Chia JK, Nakata MM, Park SS, et al. Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1995;21:1520
   PubMed Web of Science ®Google Scholar
• Approval of Synercid for certain vancomycin resistant infection. Food and Drug Administration, US Department of Health and Human Services. Available from www.fda.gov/bbs/topics/ANSWERS/ANS00976.html [Accessed 25 February 2009]
   Google Scholar
• Linezolid for the treatment of vancomycin resistant enterococcal infections: a double-blind trial comparing 600 mg linezolid every 12 hours with 200 mg linezolid every 12 hours (study report M/1260/ 0054A). Peapack, NJ: Pharmacia and Upjohn; 1999
   Google Scholar
• Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin–dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53:646-9
   PubMed Web of Science ®Google Scholar
• Linden P, Pasculle AW, McDevitt D, et al. Effect of quinupristin–dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: comparison with a control cohort. J Antimicrob Chemother 1997;39(Suppl A):145-51
   PubMedGoogle Scholar
• Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin–dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008;46:30-6
   PubMed Web of Science ®Google Scholar
• Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin–dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999;44:251-61
   PubMed Web of Science ®Google Scholar
• Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin–dalfopristin. Clin Infect Dis 2001;33:1816-23
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Golan Y, Lamp KC, et al. Daptomycin in the treatment of bacteremia. Am J Med 2007;120(10 Suppl 1):S21-7
   PubMed Web of Science ®Google Scholar
• Kvirikadze N, Suseno M, Vescio T, et al. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis 2006;38:290-2
   PubMed Web of Science ®Google Scholar
• Poutsiaka DD, Skiffington S, Miller KB, et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007;54:567-71
   PubMed Web of Science ®Google Scholar
• Swoboda S, Hoppe-Tichy T, Geiss HK, et al. Septic shock due to vancomycin-resistant enterococci infection. tigecycline monotherapy. Anaesthesist 2007;56:169-74
   PubMedGoogle Scholar
• Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate- use program. Clin Infect Dis 2003;36:159-68
   PubMed Web of Science ®Google Scholar
• El Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transplant Infect Dis 2003;5:121-5
   PubMedGoogle Scholar
• Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179
   PubMed Web of Science ®Google Scholar
• Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002;42:137-9
   PubMed Web of Science ®Google Scholar
• Bae HG, Sung H, Kim MN, et al. First report of a linezolid- and vancomycin-resistant Enterococcus faecium strain in Korea. Scand J Infect Dis 2006;38:383-6
   PubMed Web of Science ®Google Scholar
• Swoboda S, Fritz S, Martignoni ME, et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 2005;56:787-9
   PubMed Web of Science ®Google Scholar
• Liao CH, Tseng SP, Fang CT, et al. First linezolid- and vancomycin-resistant Enterococcus faecium strain in Taiwan. J Antimicrob Chemother 2005;55:598-9
   PubMed Web of Science ®Google Scholar
• Johnson AP, Tysall L, Stockdale MV, et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002;21:751-4
   PubMed Web of Science ®Google Scholar
• Halle E, Padberg J, Rosseau S, et al. Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany. Infection 2004;32:182-3
   PubMedGoogle Scholar
• Bonora MG, Solbiati M, Stepan E, et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 2006;44:1153-5
   PubMed Web of Science ®Google Scholar
• Rahim S, Pillai SK, Gold HS, et al. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003;36:E146-8
   PubMed Web of Science ®Google Scholar
• Dobbs TE, Patel M, Waites KB, et al. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006;44:3368-70
   PubMedGoogle Scholar
• Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346:867-9
   PubMed Web of Science ®Google Scholar
• Bonora MG, Ligozzi M, Luzzani A, et al. Emergence of linezolid resistance in Enterococcus faecium not dependent on linezolid treatment. Eur J Clin Microbiol Infect Dis 2006;25:197-8
   PubMedGoogle Scholar
• Scheetz MH, Knechtel SA, Malczynski M, et al. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008;52:2256-9
   PubMed Web of Science ®Google Scholar
• Pai MP, Rodvold KA, Schreckenberger PC, et al. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;35:1269-72
   PubMed Web of Science ®Google Scholar
• Qi C, Zheng X, Obias A, et al. Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis. J Clin Microbiol 2006;44:1098-100
   PubMedGoogle Scholar
• Tenover FC, Williams PP, Stocker S, et al. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J Clin Microbiol 2007;45:2917-22
   PubMedGoogle Scholar
• Scheetz MH, Qi C, Noskin GA, et al. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. Diagn Microbiol Infect Dis 2006;56:407-13
   PubMedGoogle Scholar
• Winston DJ, Emmanouilides C, Kroeber A, et al. Quinupristindalfopristin for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2000;30:790-7
   PubMedGoogle Scholar
• McDonald LC, Rossiter S, Mackinson C, et al. Quinupristin–dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens. N Engl J Med 2001;345:1155-60
   PubMed Web of Science ®Google Scholar
• Werner G, Klare I, Witte W. Molecular analysis of streptogramin resistance in enterococci. Int J Med Microbiol 2002;292:81-94
   PubMed Web of Science ®Google Scholar
• Kieke AL, Borchardt MA, Kieke BA, et al. Use of streptogramin growth promoters in poultry and isolation of streptogramin-resistant Enterococcus faecium from humans. J Infect Dis 2006;194:1200-8
   PubMedGoogle Scholar
• Solway S, Vincent L, Tian N, et al. Isolation of streptogramin-resistant Enterococcus faecium from human and non-human sources in a rural community. J Antimicrob Chemother 2003;52:707-10
   PubMedGoogle Scholar
• Werner G, Klare I, Spencker FB, Witte W. Intra-hospital dissemination of quinupristin–dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. J Antimicrob Chemother 2003;52:113-5
   PubMed Web of Science ®Google Scholar
• Dowzicky M, Talbot GH, Feger C, et al. Characterization of isolates associated with emerging resistance to quinupristin–dalfopristin (synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000;37:57-62
   PubMed Web of Science ®Google Scholar
• Smith DL, Johnson JA, Harris AD, et al. Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in Enterococcus faecium. Lancet Infect Dis 2003;3:241-9
   PubMed Web of Science ®Google Scholar
• Luh KT, Hsueh PR, Teng LJ, et al. Quinupristin–dalfopristin resistance among Gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 2000;44:3374-80
   PubMed Web of Science ®Google Scholar
• Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005;41:1134-42
   PubMed Web of Science ®Google Scholar
• Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin–dalfopristin and high-dose ampicillin. Ann Pharmacother 2004;38:989-91
   PubMed Web of Science ®Google Scholar
• Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin–dalfopristin and high-dose ampicillin. South Med J 2003;96:818-20
   PubMedGoogle Scholar
• Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin–dalfopristin and high-dose ampicillin. Ann Pharmacother 2004;38:989-91
   PubMed Web of Science ®Google Scholar
• Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007;45:1343-6
   PubMedGoogle Scholar
• Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343-4
   PubMed Web of Science ®Google Scholar
• Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13
   PubMed Web of Science ®Google Scholar
• Donskey CJ, Chowdry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925-32
   PubMed Web of Science ®Google Scholar
• Paterson DL, Muto CA, Ndirangu M, et al. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 2008;52:465-9
   PubMed Web of Science ®Google Scholar
• Vernon MO, Hayden MK, Trick WE, et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006;166:306-12
   PubMedGoogle Scholar
• Hayden MK, Bonten MJ, Blom DW, et al. Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures. Clin Infect Dis 2006;42:1552-60
   PubMed Web of Science ®Google Scholar
• Goodman ER, Platt R, Bass R, et al. Impact of an environmental cleaning intervention on the presence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci on surfaces in intensive care unit rooms. Infect Control Hosp Epidemiol 2008;29:593-9
   PubMed Web of Science ®Google Scholar
• Weinstein MR, Dedier H, Brunton J, et al. Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1999;29:361-6
   PubMed Web of Science ®Google Scholar
• Wong MT, Kauffman CA, Standiford HC, et al. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001;33:1476-82
   PubMed Web of Science ®Google Scholar
• Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomized controlled trial. Med J Aust 2007;186:454-7
   PubMed Web of Science ®Google Scholar